Review ArticleReview Article
Open Access
Aldo-Keto Reductases and Cancer Drug Resistance
Trevor M. Penning, Sravan Jonnalagadda, Paul C. Trippier and Tea Lanišnik Rižner
Michael Gottesman, ASSOCIATE EDITOR
Pharmacological Reviews July 2021, 73 (3) 1150-1171; DOI: https://doi.org/10.1124/pharmrev.120.000122
Trevor M. Penning
Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology & Translational Therapeutics, Philadelphia, Pennsylvania (T.M.P.); Department of Pharmaceutical Science (S.J., P.C.T.) and Fred and Pamela Buffett Cancer Center (P.C.T.), University of Nebraska Medical Center and UNMC Center for Drug Discovery, Omaha, Nebraska; and Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (T.L.R.)
Sravan Jonnalagadda
Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology & Translational Therapeutics, Philadelphia, Pennsylvania (T.M.P.); Department of Pharmaceutical Science (S.J., P.C.T.) and Fred and Pamela Buffett Cancer Center (P.C.T.), University of Nebraska Medical Center and UNMC Center for Drug Discovery, Omaha, Nebraska; and Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (T.L.R.)
Paul C. Trippier
Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology & Translational Therapeutics, Philadelphia, Pennsylvania (T.M.P.); Department of Pharmaceutical Science (S.J., P.C.T.) and Fred and Pamela Buffett Cancer Center (P.C.T.), University of Nebraska Medical Center and UNMC Center for Drug Discovery, Omaha, Nebraska; and Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (T.L.R.)
Tea Lanišnik Rižner
Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology & Translational Therapeutics, Philadelphia, Pennsylvania (T.M.P.); Department of Pharmaceutical Science (S.J., P.C.T.) and Fred and Pamela Buffett Cancer Center (P.C.T.), University of Nebraska Medical Center and UNMC Center for Drug Discovery, Omaha, Nebraska; and Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (T.L.R.)
Michael Gottesman
Roles: ASSOCIATE EDITOR
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Review ArticleReview Article
Aldo-Keto Reductases and Cancer Drug Resistance
Trevor M. Penning, Sravan Jonnalagadda, Paul C. Trippier and Tea Lanišnik Rižner
Pharmacological Reviews July 1, 2021, 73 (3) 1150-1171; DOI: https://doi.org/10.1124/pharmrev.120.000122
Jump to section
- Article
- Visual Overview
- Abstract
- I. Introduction to Aldo-Keto Reductases
- II. Stress Response and Nuclear Factor-Erythroid 2 p45-Related Factor 2 Induction of Aldo-Keto Reductases
- III. Somatic Mutations and Epigenetic Regulation of the Nuclear Factor-Erythroid 2 p45-Related Factor 2-Kelch-Like ECH-Associated Protein 1 Pathway
- IV. Resistance to Major Cancer Chemotherapeutics Mediated by Aldo-Keto Reductases
- V. Resistance to Antihormonal Therapies Mediated by Aldo-Keto Reductases
- VI. Inactivators of the Nuclear Factor-Erythroid 2 p45-Related Factor 2-Kelch-Like ECH-Associated Protein 1 System
- VII. Inhibitors of Aldo-Keto Reductases to Surmount Drug Resistance
- VIII. Inhibitors of Aldo-Keto Reductases to Potentiate the Effects of Chemotherapeutic Agents
- IX. Resistance Versus Disease Progression: Cause or Consequence
- X. Clinical Use of Nuclear Factor-Erythroid 2 p45-Related Factor 2 and AKR Inhibitors to Surmount Chemotherapeutic Drug Resistance
- XI. Conclusions
- Acknowledgments
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement